| | |
Per Share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | 10.00 | | | | | $ | 65,000,000 | | |
承保折扣和佣金(1)
|
| | | $ | 0.60 | | | | | $ | 3,900,000 | | |
未扣除费用的收益给我们
|
| | | $ | 9.40 | | | | | $ | 61,100,000 | | |
|
关于本招股说明书副刊
|
| | | | S-1 | | |
|
招股说明书补充摘要
|
| | | | S-2 | | |
|
THE OFFERING
|
| | | | S-6 | | |
|
有关前瞻性陈述的说明
|
| | | | S-8 | | |
|
RISK FACTORS
|
| | | | S-10 | | |
|
USE OF PROCEEDS
|
| | | | S-16 | | |
|
DILUTION
|
| | | | S-17 | | |
|
同时发行可转换票据说明
|
| | | | S-18 | | |
|
UNDERWRITING
|
| | | | S-20 | | |
|
普通股非美国持有者
|
| | | | S-31 | | |
|
LEGAL MATTERS
|
| | | | S-34 | | |
|
EXPERTS
|
| | | | S-34 | | |
|
您可以在哪里找到更多信息
|
| | | | S-34 | | |
|
通过引用并入某些信息
|
| | | | S-35 | | |
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
PROSPECTUS SUMMARY
|
| | | | 1 | | |
|
NOVAVAX
|
| | | | 1 | | |
|
RISK FACTORS
|
| | | | 2 | | |
|
USE OF PROCEEDS
|
| | | | 2 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 2 | | |
|
我们的股本说明
|
| | | | 4 | | |
|
认股权证说明
|
| | | | 6 | | |
|
DESCRIPTION OF OUR UNITS
|
| | | | 7 | | |
|
DIVIDEND POLICY
|
| | | | 8 | | |
|
LEGAL MATTERS
|
| | | | 8 | | |
|
EXPERTS
|
| | | | 8 | | |
|
您可以在哪里找到更多信息
|
| | | | 8 | | |
|
通过引用并入某些信息
|
| | | | 9 | | |
|
Offering price per share
|
| | | | | | | | | $ | 10.00 | | |
|
截至2022年9月30日的每股有形账面净值
|
| | | $ | (8.82) | | | | | | | | |
|
可归因于此次发行的每股有形账面净值增加
|
| | | $ | 1.39 | | | | | | | | |
|
本次发行生效后的调整后每股有形账面净值
|
| | | | | | | | | $ | (7.43) | | |
|
对新投资者每股有形账面净值的摊薄
|
| | | | | | | | | $ | (17.43) | | |
Name
|
| |
Number of Shares
|
| |||
J.P. Morgan Securities LLC
|
| | | | 2,600,000 | | |
Jefferies LLC
|
| | | | 1,950,000 | | |
Cowen and Company LLC
|
| | | | 1,462,500 | | |
B.莱利证券公司
|
| | | | 243,750 | | |
温赖特有限责任公司
|
| | | | 243,750 | | |
Total
|
| | | | 6,500,000 | | |
| | |
Without exercise of
option to purchase additional shares |
| |
With full exercise of
option to purchase additional shares |
| ||||||
Per Share
|
| | | $ | 0.60 | | | | | $ | 0.60 | | |
Total
|
| | | $ | 3,900,000 | | | | | $ | 4,485,000 | | |
| Section 96(1) (a) | | |
要约、转让、出售、放弃或交付对象为:
(I)其通常业务或其部分通常业务是以委托人或代理人的身份从事证券交易的人;
(二)南非公共投资公司;
(三)受南非储备银行监管的个人或实体;
(四)南非法律授权的金融服务提供商;
(V)南非法律承认的金融机构;
(br}(Vi)(C)、(D)或(E)项所述任何个人或实体的全资附属公司,以退休基金获授权投资组合管理人或集体投资计划管理人的身分行事(每宗个案均根据南非法律正式登记为代理人);或
|
|
| Section 96(1) (b) | | | 任何作为委托人的单一收件人预期购买证券的总成本等于或大于1,000,000兹罗提,或根据《南非公司法》第96(2)(A)条在南非政府公报中公布的更高金额。 | |
|
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
|
PROSPECTUS SUMMARY
|
| | | | 1 | | |
|
NOVAVAX
|
| | | | 1 | | |
|
RISK FACTORS
|
| | | | 2 | | |
|
USE OF PROCEEDS
|
| | | | 2 | | |
|
PLAN OF DISTRIBUTION
|
| | | | 2 | | |
|
我们的股本说明
|
| | | | 4 | | |
|
认股权证说明
|
| | | | 6 | | |
|
DESCRIPTION OF OUR UNITS
|
| | | | 7 | | |
|
DIVIDEND POLICY
|
| | | | 8 | | |
|
LEGAL MATTERS
|
| | | | 8 | | |
|
EXPERTS
|
| | | | 8 | | |
|
您可以在哪里找到更多信息
|
| | | | 8 | | |
|
通过引用并入某些信息
|
| | | | 9 | | |